A new immunoassay was developed to detect denaturation of type II collagen in osteoarthritis (OA). A peptide, al(II)-CBllB, located in the CB11 peptide of type II collagen, was synthesized and used to produce a monoclonal antibody (COL2-3/4m) of the IgG,(K) isotype. This reacts with a defined epitope in denatured but not native type II collagen and the a3 chain of type XI collagen. The latter is present in very small amounts (about 1% wt/wt) in cartilage relative to the al (II) chain. By using an enzyme-linked immunosorbent assay, type II collagen denaturation and total type II collagen content were determined. The epitope recognized by the antibody was resistant to cleavage by a-chymotrypsin and proteinase K which were used to extract al (II)-CB11B from the denatured (a-chymotrypsin soluble) and residual native (proteinase K soluble) collagen a-chains, respectively, present in human femoral articular cartilage. Type II collagen content was significantly reduced from a mean (range) of 14% (9.2-20.8%) of wet weight in 8 normal cartilages to 10.3% (7.4-15.0%) in 16 OA cartilages. This decrease, which may result in part from an increased hydration, was accompanied by an increase in the percent denaturation of type II collagen in OA to 6.0% of total type II collagen compared with 1.1% in normal tissue. The percent denaturation was ordinarily greater in the more superficial zone than in the deep zone of OA cartilage. (J. Clin. Invest.
Introduction
Type II collagen and aggrecan (a large, aggregating proteoglycan) are the two major components ofthe extracellular matrix of cartilage. The collagen, which is present in a fibrillar form, provides tensile strength whereas the aggrecan is responsible for compressive stiffness of cartilage (1) (2) (3) . Degradation and loss from the matrix of either of these molecules could contribute significantly to destruction of articular cartilage and loss of its function in patients with arthritic diseases. The proteolytic degradation of proteoglycan has been widely studied (3) (4) (5) (6) . In contrast, there have been very few studies of type II collagen degradation, owing to a lack of adequate methodology with which to detect damage to specific collagen molecules and their release. Electron microscopic studies have revealed damage to collagen fibrils in articular cartilage in RA (7) . Damage to collagen at the junction of cartilage with pannus (8) and at the articular surface (9) has also been noted in RA. In osteoarthritis (OA),' Venn and Maroudas (10) used estimations of hydroxyproline to demonstrate a decrease in the collagen content as a percentage of wet weight of femoral head cartilage compared with normal (postmortem) cartilage. Such analyses cannot distinguish different types of collagen in the cartilage.
Specific studies of damage to type II collagen resulting in denaturation (unwinding) ofthe triple helix were first made by Dodge and Poole ( 11 ) and Dodge et al. ( 12) , who showed that a polyclonal rabbit antiserum raised against cyanogen bromide peptides of type II collagen will react specifically with denatured, but not native (triple helical), type II collagen a chains or fragments thereof containing the recognized epitopes. The antiserum was used to demonstrate, by immunolocalization and immunochemical analysis ofcartilage extracts, type II collagen cleavage in situ in OA and RA and type II collagen denaturation induced when cartilage is cultured with interleukin- 1. These studies clearly demonstrated that arthritic cartilages exhibit increased staining for type II collagen denaturation. Moreover, whereas in aging and OA damage was first observed at and close to the articular surface, in RA early damage was usually most pronounced around chondrocytes in the deep zone, adjacent to subchondral bone (11, 12) . This revealed that there are differences in the sites ofcleavage oftype II collagen that may be due to differences in the pathogenesis of these diseases (see also reference 3 for a discussion). The fact that early damage to type II collagen is predominantly pericellular/ territorial suggests that in the majority of cases collagen damage was mediated by the chondrocyte. Subsequently we showed, with a specific, nontoxic hydroxamate inhibitor, that cleavage of type II collagen in human articular cartilage is mediated by metalloproteinases released from chondrocytes ( 13) . Other immunochemical studies with the antiserum revealed that the metalloproteinase collagenase may in part be responsi- 1 . Abbreviations used in this paper: HDC, heat-denatured type II collagen; OA, osteoarthritis; TPCK, N-tosyl-L-phenylalanine chloromethyl ketone. ble for this denaturation. This is the only mammalian proteinase that can cleave the triple helix of this molecule (4) .
At that time it was not possible to quantitate collagen denaturation by immunoassay. Moreover, because we showed that denatured collagen is retained in the fibril and not released ( 1 1, 12) , it was necessary to develop a means of selectively extracting denatured type II collagen so that it could be measured. In order to assay collagen fragments and conduct other specific immunological studies, it is preferable to determine the content ofjust one epitope, of known location within the collagen molecule, by using a single monoclonal antibody in an immunoassay. Under these circumstances any one fragment will react either fully or not at all in the assay and so the quantity of denatured collagen and identity of such fragments containing the defined epitope can be more accurately determined. Furthermore, a protease with gelatinase-like activity that cleaves neither the chosen epitope nor native (helical) collagen could theoretically be used to extract those denatured collagen achains that are retained in the fibril.
To study damage to type II collagen in articular cartilage in arthritis, we developed an immunoassay based on our earlier immunochemical work ( 1 1, 12) . Here we describe and use this assay to provide the first quantitative evidence for increased damage to type II collagen in situ and decreased content of total type II collagen in OA cartilage.
Methods
Tissue. Human articular cartilages were removed from the anterior (loaded) region of the femoral condyles of adult knee joints. OA cartilages were obtained at surgery from patients undergoing total joint arthroplasty. Site-matched nonarthritic articular cartilages of normal appearance were obtained at autopsy within 15 h postmortem from individuals with no known history or signs ofarthritic/joint abnormalities. Patient details and Mankin grades of the normal and OA cartilage specimens are shown in Table I . Previously, cartilage from these same sites has been analyzed for the proteoglycan aggrecan (6) .
Preparation ofcartilage plugs. In that cutting cartilage can produce denaturation of type II collagen, care was taken to prepare defined plugs of cartilage using a specially made, standardized, stainless steel punch. This avoided variable results and the increased denaturation obtained by dicing the cartilage with a scalpel or by preparing frozen sections (data not shown). Wherever possible, a full depth slice of cartilage was taken from each femoral condyle (medial and lateral) and two full-depth cylindrical plugs, each -4 mm in diameter by 2 mm deep, were prepared from each slice using the steel punch. One of the plugs was used for the histological assessment of Mankin grade, as previously described (6, 14) . This did not include analysis of the calcified cartilage, hence the maximum grade in the group of OA cartilages was only 13. The other plug was used for the extraction and assay of type II collagen. In some experiments the full-depth plugs were approximately divided into an upper and a lower half by using a scalpel. The ( 15) . Only the cyanogen bromide peptide 11 of the al (II) chain was analyzed for hydrophobicity/hydrophilicity, because this 279-amino acid peptide resides within the triple helix and has already been shown to be immunogenic in rabbits ( 11 ) . Additional criteria for selection of a suitable peptide sequence were as follows: (a) The epitope should not include any hydroxylysine residues (these could be involved in crosslink formation and may be substituted with carbohydrate chains that could block antibody-binding). (b) The epitope should be well conserved between species (to permit species cross-reactivity). (c) The epitope should have minimal homology with sequences from other proteins and collagen a chains. (d) The epitope should be resistant to hydrolysis by proteinase K and a-chymotrypsin, which were used to extract from cartilage native and denatured collagen respectively.
For the purposes of analysis, it was assumed that all proline and lysine residues in the "Y" position of the Gly-X-Y repeat sequence were hydroxylated. However, the hydroxyl group did not appear to contribute significantly to the hydrophobicity of cyanogen bromide peptide 11, in that the hydrophobicity/hydrophilicity profile was almost identical when hydroxyproline and hydroxylysine hydropathy values were replaced with those of proline and lysine respectively.
Peptides up to 23 amino acids long containing a centrally located hydrophilic domain, with an amino-terminal cysteine for conjugation to ovalbumin and a carboxy terminal tyrosine (for iodination if required), were synthesized at a 0.25-mmol scale, using standard Fmoc (9-fluorenylmethoxycarbonyl) chemistry, on an model 431A solidphase peptide synthesizer (Applied Biosystems, Inc., Foster City, CA). The crude peptides were purified by reverse-phase chromatography (Prep-I 0 Aquapore C8 column, Applied Biosystems Inc.) using an acetonitrile gradient in 0.1% trifluoroacetic acid.
Preparation ofa monoclonal antibody. The chosen peptide, a I (11) -CB 1 I B, was conjugated to ovalbumin through its amino-terminal cysteine, using the coupling reagent bromoacetic acid-N-hydroxysuccinimide ester (Sigma Chemical Co., St. Louis, MO), as previously described (16) . BALB/c mice were immunized five times at 2-wk intervals by i.p. injection with 100 ,gg ofthe conjugated peptide emulsified with complete (first immunization) or incomplete (subsequent immunizations) Freund's adjuvant. Serum samples from the mice were then tested in an ELISA (see below) for reactivity with both peptide and heat-denatured type II collagen (HDC). Splenocytes from the mouse showing the best serum antibody response were fused to SP2 /0 myeloma cells and monoclonal antibodies were prepared using conventional hybridoma technology ( 17, 18 Proteolytic cleavage ofHDC and al (II) -CB] iB peptide by clostridial collagenase. HDC and a I (II)-CBl lB were dissolved in Tris containing 5 mM CaCl2 and 14 U/ml chromatographically purified collagenase form III (bacterial collagenase) from Clostridium histolyticum (Advance Biofactures Corp., Lynbrook, NY). Controls contained HDC or al (II)-CB 1I B in Tris with 5 mM CaCl2 but no collagenase, or collagenase in Tris with 5 mM CaCl2 but no HDC, nor a I (II)-CB I I B peptide. All the tubes were incubated overnight at 370C and the collagenase was then inhibited by the addition of EDTA to a final concentration of0.1 M. The samples were each tested for reactivity in the inhibition ELISA for denatured type II collagen.
Proteolytic cleavages ofHDC by a-chymotrypsin andproteinase K.
Aliquots of HDC at concentrations of 0.25 mg/ml or less were prepared in Tris containing 0.5 mg/ml of type VII a-chymotrypsin or proteinase K (both from Sigma Chemical Co.). Control tubes contained only HDC, or 0.5 mg/ml a-chymotrypsin or 0.5 mg/ml proteinase K. The samples were all incubated overnight at 37°C (a-chymotrypsin) or 56°C (proteinase K). The a-chymotrypsin was inactivated by addition of 115 jig/ml N-tosyl-L-phenylalanine chloromethyl ketone (TPCK; Sigma Chemical Co.) in Tris, predissolved in ethanol (4% vol/vol, final concentration). Proteinase K was inactivated by boiling for 10 min. Degradation ofthe HDC by each proteinase was confirmed by SDS-PAGE (see below). The degraded collagens and control samples were each tested for reactivity in the inhibition ELISA for denatured type II collagen.
Extraction and assay ofnative and denatured collagen from cartilage plugs. Because a-chymotrypsin, like all mammalian proteinases apart from interstitial collagenase, cannot cleave intact, triple helical type II collagen, this enzyme can be used to selectively degrade any collagen in cartilage which has already been denatured in situ. Conversely, cartilage can be fully solubilized by incubation with proteinase K at 56°C (its optimal temperature). Complete denaturation of the extracted collagen can then be ensured by heating. Therefore cartilage plugs were routinely extracted, first with a-chymotrypsin and then proteinase K. The plugs were distributed individually into Eppendorf tubes. To each tube was added 500 Ml of 1 mg/ml a-chymotrypsin in Tris containing 1 mM iodoacetamide, 1 mM EDTA, and 10 ,jg/ml pepstatin-A (all from Sigma Chemical Co.). The samples were incubated overnight at 37°C. The a-chymotrypsin was inhibited by addition of 200 Mul per tube of 0.4 mg/ml TPCK in Tris containing 4% vol/vol ethanol. The a-chymotrypsin extract was separated from the residue. Each residue was then digested with 500 Ml of 1 mg/ml proteinase K in Tris containing the same protease inhibitors as described above. After digestion overnight at 56°C, no residue remained. The proteinase K was inactivated and the extracted collagen fully denatured by boiling the samples for 10 min. In order to measure any native collagen extracted by a-chymotrypsin, a 300 Al aliquot of each a-chymotrypsin extract was mixed with 100 ,ul ofthe 1 mg/ml proteinase K solution and incubated and then boiled as described for cartilage residues. The TPCK-inhibited a-chymotrypsin and boiled proteinase K had no inhibitory effect themselves in the inhibition ELISA.
Digestion ofextracted collagen peptides with clostridial collagenase to confirm susceptibility ofthe extracted CBR JB epitope to cleavage by this enzyme. Collagens were extracted from plugs of OA cartilage with a-chymotrypsin and proteinase K and the proteinases inhibited as described above. The extracts were each divided into two aliquots. To one of these was added 5 mM CaCl2 and 14 U/ml clostridial collagenase and to the other, 5 mM CaCl2 only. A control tube contained collagenase in Tris with 5 mM CaCl2 but no cartilage extract. All tubes were incubated overnight at 37°C and the collagenase activity was inhibited with EDTA as described above. The samples were all tested for reactivity in the inhibition ELISA for denatured type II collagen.
Extraction of cartilage plugs with guanidinium chloride to determine the content ofnon-cross-linked collagen. In one experiment, two adjacent full-depth plugs were taken from each of five OA cartilages. One ofthe plugs from each specimen was extracted with a-chymotrypsin as described above. The other plug from each specimen was extracted for 72 h at 4°C with gentle rocking in 4 mM guanidinium chloride, 0.1 M Tris-HCl, pH 7.3 containing 1 mM iodoacetamide, 1 mM EDTA, and 10 jg/ml pepstatin-A. The guanidinium chloride ex-tracts were dialyzed exhaustively against Tris using a membrane with a molecular weight cutoffof 3,500. A 300-,al aliquot ofeach ofthe a-chymotrypsin and guanidinium chloride extract was mixed with 100 td of I mg/ml proteinase K, incubated overnight at 560C, and then boiled to inhibit the proteinase. All the extracts were tested for reactivity in the inhibition ELISA for denatured type II collagen.
Electrophoresis and immunoblotting. SDS-PAGE of purified collagens was performed using 7.5% and 10%, 1-mm-thick, 7-cm X 8-cm mini-Protean gels, stained with either Coomassie Brilliant Blue or silver stain (Bio-Rad Laboratories, Mississuaga, ON), as described by Dodge and Poole ( 11) . The electrophoresed samples were transferred to a nitrocellulose membrane which was then blocked overnight at 40C with PBS containing 3% wt/vol BSA (PBS-3% BSA) ( 11) . The membrane was incubated for 1 h at room temperature with the monoclonal antibody or control mouse ascitic fluid diluted in PBS-3% BSA. After three washes with PBS-Tween, the membrane was incubated at 30 min at room temperature with the alkaline phosphatase conjugated goat anti-mouse second-step antibody described above, diluted 1 in 100 with PBS-3% BSA. The membrane was washed well with PBS-Tween and once with distilled water. Alkaline phosphatase substrate solution was prepared from a commercial kit (Bio-Rad) employing 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium. It was added and incubated with the membrane at room temperature until optimal color had developed. 
Results
Identification ofan immunogenic peptide. Five hydrophilic domains (hydrophobicity less than -1.0) were identified from the hydrophobicity profile ofthe cyanogen bromide peptide 11 of human type II collagen (Fig. 1) . A 21-amino acid sequence (-Gly-Lys-Val-Gly-Pro-Ser-Gly-Ala-Hyp-Gly-Glu-Asp-GlyArg-Hyp-Gly-Pro-Hyp-Gly-Pro-Gln-) from one of these domains satisfied the four additional criteria for peptide sequence selection described above, in Methods. The peptide, a I(II)-CB 11 B, was synthesized with an additional amino-terminal cysteine (for conjugation) and carboxy-terminal tyrosine (for iodination if needed for an RIA), coupled to ovalbumin, and used to immunize mice. isotype. The specific peptide sequence recognized by the monoclonal was identified by synthesizing short, overlapping peptides from within the sequence of a 1 (II )-CB 1 l B and testing these for reactivity with the monoclonal (data not shown). Maximum reactivity was retained with a 13-amino acid pep- (Fig. 2) . None of the collagens reacted with a control antibody, 6B, which has the same isotype as COL2-3 /4m (see reference 22 and legend to Fig. 2 ). COL2-3/4m cross-reacts with the a3 chain of type XI collagen, the sequence of which is identical to that ofthe a 1 (II) chain, but is more heavily glycosylated (23, 24 Fig. 3 A. The inhibition profiles for HDC and a 1 (II )-CB 11 B were essentially parallel (Fig. 3 A) . On a molar basis the concentration ranges of antigen producing linear inhibition were similar for al (II)-CBl lB and HDC (Fig. 3 B) , although (Fig. 4) .
It was important to demonstrate that the inhibition ELISA was specific for denatured type II collagen. Accordingly, bovine type II collagen was prepared at various concentrations in the native and heat-denatured forms and assayed for a I(11)-CBl lB. Table II shows that only background levels of denatured a chain, measured as a (II)-CBl lB could be detected in the native type II collagen preparation. The al (II)-CBl lB epitope could not be detected by immunoassay in samples of heat denatured types I or III collagen (Table III) , confirming the finding from Western blotting that COL2-3/4m does not react with these molecules (see above).
Denaturation oftype II collagen after cleavage by interstitial collagenase. Cleavage of purified native type II collagen by recombinant human interstitial collagenase produced the characteristic three-quarter and one-quarter products, seen by SDS-PAGE, but only the three-quarter product was detected by immunoblotting with COL2-3/4m (Fig. 5 A) . When the collagenase-cleaved collagen was assayed for a (II)-CBl lB, it was found that 56% of the collagen had been denatured compared to just 11% denaturation in the native collagen control which had been incubated under the same conditions but without collagenase. The partial denaturation of the control collagen was due to the prolonged incubation (20 h) at 30 [la (II) CB1 I Bl pWmQ) with cyanogen bromide produced a number of peptides, including CB8, CB10, and CB1 1, as seen by SDS-PAGE and silver staining (Fig. 5 B) . The only peptide to be detected by immunoblotting with monoclonal COL2-3/4m was, as expected, based on the location of the epitope, CB1 1 (Fig. 5 B) . Epitope in peptide al (II) -CBIIB is cleaved by clostridial collagenase. When clostridial collagenase alone was inhibited with 100 mM EDTA and assayed for al(II)-CBllB it produced a small amount of inhibition, equivalent to a background level of 0.85 tg/ml al (11)-CB1 lB (Table IV) (Table IV) , demonstrating hydrolysis of the epitope by clostridial collagenase. Therefore this property can be used to confirm the identity of the epitope in ELISA inhibition assays of samples containing it.
Proteolytic cleavage ofHDC. HDC was extensively cleaved into small, undetectable peptides by both a-chymotrypsin and proteinase K, as judged by SDS-PAGE (data not shown) but without loss of the epitope (Table V) (Fig. 6 ).
The proportion of denatured type II collagen was significantly increased in OA compared to normal cartilage (Fig. 6 ).
The mean values for the percentage of denatured collagen in normal and OA cartilages were 1.1% and 6.0% respectively.
There were no correlations between either total or percent denatured type II collagen and the degree of cartilage degradation recorded as the Mankin grade of OA cartilages (Fig. 7) .
Digestion ofextracted collagen with clostridial collagenase.
It was important to demonstrate that inhibition observed in the a (11)-CB lB ELISA by a-chymotrypsin and proteinase K Values for al(II)-CBI lB by inhibition ELISA are shown. Aliquots of HDC at 0.25 mg/ml were prepared in Tris containing 0.5 mg/ml of type VII a-chymotrypsin or proteinase K. Control tubes contained only HDC, or 0.5 mg/ml a-chymotrypsin or 0.5 mg/ml proteinase K. The samples were incubated overnight at 370C (a-chymotrypsin) or 560C (proteinase K). The a-chymotrypsin was inactivated by addition of 15 qSg/ml TPCK. Proteinase K was inactivated by boiling for 10 min.
extracts of human cartilage was due entirely to the a 1(11)-CB1 1 B epitope. Since the epitope is destroyed by treatment with clostridial collagenase (see above and Table IV) , some extracts were treated with this enzyme as a control for specificity. There was a loss of immunoreactivity in each case (Table  VI) , demonstrating the specificity of the assay for the a I (II)-CB1 1 B epitope in the cartilage extracts.
Variation in total and denatured type II collagen with depth of cartilage. From cartilage in which specimens could be obtained (minimum thickness, 2 mm), plugs were divided into the upper 1 mm (articular zone) and lower 1 mm (deeper zone; these are approximate thicknesses) using a scalpel and a specially constructed slicing bed. The total type II collagen concentration was higher in the deeper (lower 1 mm) compared to more superficial (upper 1 mm) cartilage for four offive normal and five ofeight OA specimens (Figs. 8, A and C) . The percentage ofdenatured collagen did not vary significantly with depth in normal cartilage (Fig. 8 B) . In one sample there was a high level ofdenatured collagen in the more superficial cartilage and increased denaturation in the deeper cartilage too. In two ofthe four other specimens, denaturation was enhanced in the more superficial cartilage, otherwise it was similar in each zone or higher in the deeper cartilage. For of denatured collagen was significantly higher in the upper 1-mm zone (Fig. 8 D) . This difference was seen in six of eight specimens. Of the other two specimens one showed the opposite trend and the other exhibited similar denaturation in the upper and lower levels. There was no correlation between total or percent denatured collagen in either the upper or lower zones and Mankin grade of the full-depth cartilage for normal and OA specimens (data not shown). The mean values oftotal and denatured collagen in the upper and lower 1-mm zones are shown in Table VII , for comparison of each zone in OA with the same zone in normal cartilage. In OA, total collagen content was only significantly reduced in the deeper cartilage of OA compared to normal. Similarly, type II collagen denaturation was only significantly increased in the lower zone of OA compared to normal cartilage. The differences in the percentage of denatured collagen in either region were not as marked as the changes seen in full-depth plugs. However it should be noted that for the depth-study, cartilage was taken from the thickest region of OA tissue and this may have been less degraded than cartilage from the thinner tissue sites.
Guanidinium chloride extracts ofOA cartilage. In order to determine if the type II collagen extracted from cartilage by a-chymotrypsin was mostly derived from fibril-associated, cross-linked collagen or from nonfibrilar, non-cross-linked a chains, a comparison was made of extraction by a-chymotrypsin and 4 M guanidinium chloride. The latter is a chaotropic reagent which can only extract the nonfibrilar, non-crosslinked collagen molecules. Adjacent plugs ofcartilage from five OA patients were extracted with a-chymotrypsin or guanidinium chloride. Far less type II collagen was extracted with 4 M guanidinium chloride than with a-chymotrypsin. For the five OA specimens examined the mean±SD total (native + denatured) type II collagen extracted by guanidinium chloride and a-chymotrypsin was 0.019±0.003 and 0. 164±0.012 ,ug/mg wet weight, respectively. Therefore the amount of type II collagen extracted by 4 M guanidinium chloride is 11.6% of that extracted by a-chymotrypsin, suggesting that most of the denatured material extracted with a-chymotrypsin is derived from cross-linked fibrils rather than a pool of newly synthesized, non-cross-linked a chains or peptides thereof. Of the type II collagen extracted with guanidinium chloride or a-chymotrypsin, only a small proportion (10.5% and 7.3%, respectively) was native collagen (detected after digestion with protienase K). However, we have found that incubation ofpurified native type II collagen for 72 h at 4°C in 4M guanidinium chloride, followed by dialysis into Tris, causes over 90% of the collagen to denature, as judged by assaying for al (11)-CB1 lB (data not shown). Therefore, it is likely that most of the a 1 (II)-CB1 lB extracted with guanidinium chloride is contained within newly synthesized molecules that are denatured by the extraction procedure.
Ofthe collagen extracted with a-chymotrypsin, the amount ofnative type II collagen was too small to be detected by immunoblotting ofa-chymotrypsin extracts (Fig. 9) . Moreover, peptides bearing the epitope recognized by antibody COL2-3/4m were too small to detect under the conditions of electrophoresis.
Discussion
The degeneration of cartilage, which is an integral feature of both OA and RA, involves localized loss of the proteoglycan aggrecan, its degradation (5, 6) and eventual loss offunction of this tissue (25) (26) (27) ). The tissue is composed ofa fibrillar organization of type II collagen (3) which endows cartilage with its tensile strength ( 1, 2). With increasing age there is a progressive reduction ofthe tensile properties offemoral head cartilage (28). This is not observed in the talus of the ankle joint where the incidence of osteoarthritis is relatively low compared to that observed in the hip or knee (28). In the present study we show that damage to type II collagen, measured as denaturation (unwinding) of the triple helix, is detectable in adult human femoral condylar cartilage and is increased in OA cartilage. This damage in OA is accompanied by a net reduction in the total type II collagen content. Previously, a loss of tensile properties was observed in OA cartilage, indicative of damage to type II collagen (25) (26) (27) . The present studies reveal that the reduced tensile strength in part relates to damage to the triple helix of type II collagen leading to denaturation (unwinding). It also correlates with an apparent net reduction in the content of this molecule in OA cartilage, previously indicated by a reduction in total cartilage collagen content measured as hy- Fig. 9 .
likely reflects denaturation of type II collagen present within cross-linked fibrils, often remote from chondrocytes. If the guanidinium chloride extractable pool represents denatured, newly synthesized collagen then the amount of this which is present in the cartilage accounts for a very small proportion of the denatured collagen. Studies are in progress to examine this question further.
Until we developed this new methodology, starting with our work on the polyclonal antiserum (4), unwinding of the triple helix of type II collagen could not be detected in situ. To accurately quantitate degradation ofcollagen fibrils in cartilage it was necessary to develop an assay based on the use of a monoclonal antibody to a defined epitope of known location and which can be extracted intact, using selected proteinases to extract it first from nonhelical a-chains and then from helical molecules. We identified and synthesized such an epitope located in the CB1 1 peptide and produced a monoclonal antibody to the synthetic peptide. The epitope is recognized in denatured but not native type II collagen a chains. This has made possible development of an immunoassay, used in these studies and the detection of total type II collagen. Monoclonal COL2-3/4m cross-reacts with denatured type II collagen from all mammalian species so far studied (including mouse), india b Figure 9 . cating that the epitope contained within peptide al(11)-CB1 lB is highly conserved. Importantly, binding of the antibody to the collagen a-chain is not dependent on hydroxylation of the "Y" position proline residues in the repeating Gly-X-Y triplet. This is important since it is possible that the extent of hydroxylation could change in pathological situations. Also, the epitope does not contain any potential crosslinking residues. Antibody COL2-3/4m cross-reacts with the a3(XI) chain, which is considered to be the same gene product as the a 1(II)-chain, although it is more heavily glycosylated (23, 24) . This cross-reactivity should not interfere with the quantitation of native or denatured type II collagen since there is only one a3(XI)-chain per molecule of type XI collagen, which represents no more than 1% oftotal collagen a chains in cartilage (30) . The antibody does not cross-react with any other collagen or protein examined. Moreover, the epitope sequence is not present in any other known protein sequence.
Continuation of these studies should permit an improved understanding ofthe mechanisms involved in the denaturation of type II collagen in arthritis and may lead to a means of regulating this pathogenic process. Antibody COL2-3/4m will be used to detect collagen fragments released from articular cartilage in vitro and in vivo. The latter may provide a means of investigating collagen II degradation in patients with arthritis.
